Photo Credit: Getty Images
Merck & Co. has launched a sweeping cost-cutting initiative, aiming at trimming $3 billion in annual expenses by the end of 2027 as it navigates shrinking vaccine revenues and braces for the expiration of its best-selling drug's patent protections.
The pharmaceutical giant announced on Tuesday that it would begin restructuring operations to reallocate capital toward its pipeline and newly launched products. CEO Rob Davis framed the decision as a necessary pivot: "We're redirecting resources from mature segments to accelerate growth in emerging assets," he told analysts. "This is about positioning ourselves to lead through the decade, not just survive it."
The move comes amid growing investor anxiety over the future of Keytruda, Merck's flagship cancer immunotherapy. The drug, which generated $7.96 billion in second-quarter revenue, is expected to lose U.S. patent protection in 2028. While sales rose 9% year over year, analysts worry about Merck's readiness for what's been called a looming "patent cliff."
Adding to the pressure, President Donald Trump's trade policies have introduced tariffs on pharmaceutical imports. Merck has estimated a $200 million impact in 2025 alone, mostly tied to U.S.-China trade friction. Though those costs are currently manageable, the company has not ruled out further exposure.
Meanwhile, second-quarter earnings fell short of expectations. Merck posted revenue of $15.81 billion, slightly below Wall Street's forecast of $15.89 billion, and a 2% decline from the same period last year. Net income dropped to $4 43 billion, or $1.76 per share, down from $5.46 billion a year earlier. The company narrowed its 2025 full-year earnings guidance to $8.87–$8.97 per share.
The pharmaceutical giant announced on Tuesday that it would begin restructuring operations to reallocate capital toward its pipeline and newly launched products. CEO Rob Davis framed the decision as a necessary pivot: "We're redirecting resources from mature segments to accelerate growth in emerging assets," he told analysts. "This is about positioning ourselves to lead through the decade, not just survive it."
The move comes amid growing investor anxiety over the future of Keytruda, Merck's flagship cancer immunotherapy. The drug, which generated $7.96 billion in second-quarter revenue, is expected to lose U.S. patent protection in 2028. While sales rose 9% year over year, analysts worry about Merck's readiness for what's been called a looming "patent cliff."
Adding to the pressure, President Donald Trump's trade policies have introduced tariffs on pharmaceutical imports. Merck has estimated a $200 million impact in 2025 alone, mostly tied to U.S.-China trade friction. Though those costs are currently manageable, the company has not ruled out further exposure.
Meanwhile, second-quarter earnings fell short of expectations. Merck posted revenue of $15.81 billion, slightly below Wall Street's forecast of $15.89 billion, and a 2% decline from the same period last year. Net income dropped to $4 43 billion, or $1.76 per share, down from $5.46 billion a year earlier. The company narrowed its 2025 full-year earnings guidance to $8.87–$8.97 per share.
The company confirmed it would suspend shipments to China until at least the end of 2025, citing ongoing demand weakness and elevated inventories. "China's contribution to Gardasil revenue is now negligible," said CFO Caroline Litchfield.
Despite the setbacks, Merck is moving ahead with acquisitions and R&D. Its recent $10 billion takeover of Verona Pharma adds Winrevair and Ohtuvayre, two lung disease drugs, with Winrevair posting $336 million in second-quarter sales.
Still, skepticism lingers. "This is a step in the right direction," said Bernstein analyst Courtney Breen, "but more aggressive cost realignment may be necessary if Merck wants to effectively bridge the post-Keytruda era."
